



Prior Authorization Request

AFINITOR and generics, AFINITOR DISPERZ (everolimus)

Instructions

Please complete Part A and have your physician complete Part B. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. Please note that you have the right to appeal the decision made by Express Scripts Canada.

Part A – Patient

Patient information

First Name:		Last Name:	
Insurance Carrier Name/Number:			
Group Number:		Client ID:	
Date of Birth (YYYY/MM/DD):		Relationship: <input type="checkbox"/> Employee <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent	
Language: <input type="checkbox"/> English <input type="checkbox"/> French		Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	
Address:			
City:	Province:	Postal Code:	
Email address:			
Telephone (home):	Telephone (cell):	Telephone (work):	

Coordination of benefits

Patient Assistance Program	Is the patient enrolled in any patient assistance program? <input type="checkbox"/> Yes <input type="checkbox"/> No Contact Name: _____ Telephone: _____
Provincial Coverage	Has the patient applied for reimbursement under a provincial plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied *Attach decision letter*
Primary Coverage	Has the patient applied for reimbursement under a primary plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied *Attach decision letter*

Authorization

On behalf of myself and my eligible dependents, I authorize my group benefit provider, and its agents, to exchange the personal information contained on this form. I give my consent on the understanding that the information will be used solely for purposes of administration and management of my group benefit plan. This consent shall continue so long as my dependents and I are covered by, or are claiming benefits under the present group contract, or any modification, renewal, or reinstatement thereof.

Plan Member Signature

Date

Prior Authorization Request

AFINITOR and generics, AFINITOR DISPERZ (everolimus)

Part B – Prescriber

Please see instructions on page 1 and complete all sections below. Incomplete forms may result in automatic denial. Please do **not** provide genetic test information or results.

SECTION 1 – DRUG REQUESTED

<input type="checkbox"/> AFINITOR		<input type="checkbox"/> AFINITOR DISPERZ		<input type="checkbox"/> New request	
<input type="checkbox"/> Home		<input type="checkbox"/> Physician's office/Infusion clinic		<input type="checkbox"/> Hospital (outpatient)	
<input type="checkbox"/> Hospital (inpatient)		<input type="checkbox"/> Renewal request*			
Dose	Administration (ex: oral, IV, etc)	Frequency	Duration		
Site of drug administration:					

*Please submit proof of prior coverage if available

SECTION 2 – ELIGIBILITY CRITERIA

1. Please indicate if the patient satisfies the below criteria:

Renal cell carcinoma – *Not a Health Canada approved indication for AFINITOR DISPERZ*

- For the treatment of metastatic renal cell carcinoma (RCC) of clear cell morphology in an adult, AND
- The patient has had an inadequate response to treatment with a tyrosine kinase inhibitor (ie. sunitinib, sorafenib)
(Please list prior therapies in the chart below)

Neuroendocrine tumours of pancreatic origin – *Not a Health Canada approved indication for AFINITOR DISPERZ*

- For the treatment of well or moderately differentiated neuroendocrine tumours of pancreatic origin (PNET) in an adult, AND
- The patient has unresectable, locally advanced or metastatic disease that has progressed within the last 12 months

Neuroendocrine tumours of gastrointestinal or lung origin – *Not a Health Canada approved indication for AFINITOR DISPERZ*

- For the treatment of unresectable, locally advanced or metastatic, well-differentiated, non-functional neuroendocrine tumour (NET) of gastrointestinal or lung origin in an adult, AND
- The patient has documented radiological disease progression within 6 months

Advanced breast cancer – *Not a Health Canada approved indication for AFINITOR DISPERZ*

- For the treatment hormone receptor-positive, HER2-negative advanced breast cancer in a postmenopausal woman, AND
- The patient experienced recurrence or progression following treatment with letrozole or anastrozole, AND
- Everolimus will be used in combination with exemestane

Renal angiomyolipoma – *Not a Health Canada approved indication for AFINITOR DISPERZ*

- For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex (TSC) in an adult, AND
- The patient does not require immediate surgery



Prior Authorization Request

AFINITOR and generics, AFINITOR DISPERZ (everolimus)

Subependymal giant cell astrocytoma

- For the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) that have demonstrated serial growth, AND
- The patient is 1 year of age or older, AND
- The patient is not a candidate for surgical resection and immediate surgical intervention is not required

Tuberous sclerosis complex – Not a Health Canada approved indication for AFINITOR

- For the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), AND
- The patient is 2 years of age or older, AND
- The patient has an inadequate response to current therapies (*Please list prior therapies in the chart below*)

OR

- None of the above criteria applies.

Relevant additional information:

2. Please list previously tried therapies

Drug	Dosage and administration	Duration of therapy		Reason for cessation	
		From	To	Inadequate response	Allergy/Intolerance
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>

SECTION 3 – PRESCRIBER INFORMATION

Physician's Name:	
Address:	
Tel:	Fax:
License No.:	Specialty:
Physician Signature:	Date:

Please fax or mail the completed form to Express Scripts Canada®

Fax:
Express Scripts Canada Clinical Services
1 (855) 712-6329

Mail:
Express Scripts Canada Clinical Services
5770 Hurontario Street, 10th Floor
Mississauga, ON L5R 3G5